Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2002-06-11
2008-09-02
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C562S561000, C549S013000, C549S426000, C514S432000, C514S459000
Reexamination Certificate
active
07420002
ABSTRACT:
Compounds that provide for sustained systemic concentrations of GABA analogs following oral administration to animals are disclosed. Pharmaceutical compositions including, and methods using, such compounds are also disclosed.
REFERENCES:
patent: 2996431 (1961-08-01), Barry
patent: 3139383 (1964-06-01), Neville et al.
patent: 3402240 (1968-09-01), Cain et al.
patent: 3811444 (1974-05-01), Heller et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4063064 (1977-12-01), Saunders et al.
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 4088864 (1978-05-01), Theeuwes et al.
patent: 4093709 (1978-06-01), Choi et al.
patent: 4200098 (1980-04-01), Ayer et al.
patent: 4285987 (1981-08-01), Ayer et al.
patent: 4421736 (1983-12-01), Walters et al.
patent: 4434153 (1984-02-01), Urquhart et al.
patent: 4508728 (1985-04-01), Nagai et al.
patent: 4721613 (1988-01-01), Urquhart et al.
patent: 4752470 (1988-06-01), Mehta
patent: 4816263 (1989-03-01), Ayer et al.
patent: 4820523 (1989-04-01), Shtohryn et al.
patent: 4853229 (1989-08-01), Theeuwes
patent: 4908353 (1990-03-01), Yamamoto et al.
patent: 5084479 (1992-01-01), Woodruff
patent: 5094848 (1992-03-01), Brixner
patent: 5110797 (1992-05-01), Ienaga et al.
patent: 5563175 (1996-10-01), Silverman et al.
patent: 6001876 (1999-12-01), Singh
patent: 6020370 (2000-02-01), Horwell et al.
patent: 6028214 (2000-02-01), Silverman et al.
patent: 6051683 (2000-04-01), Deigin et al.
patent: 6103932 (2000-08-01), Horwell
patent: 6117906 (2000-09-01), Silverman et al.
patent: 6140366 (2000-10-01), Silverman et al.
patent: 6171615 (2001-01-01), Roussin et al.
patent: 6255345 (2001-07-01), Silverman et al.
patent: 6291526 (2001-09-01), Silverman et al.
patent: 6342529 (2002-01-01), Silverman et al.
patent: 6375987 (2002-04-01), Farah et al.
patent: 6379700 (2002-04-01), Joachim et al.
patent: 6833140 (2004-12-01), Cundy et al.
patent: 1 178 034 (2002-02-01), None
patent: 2362646 (2001-11-01), None
patent: 285929 (1971-01-01), None
patent: WO 92/09560 (1992-06-01), None
patent: WO 93/23383 (1993-11-01), None
patent: WO 97/29101 (1997-08-01), None
patent: WO 97/33858 (1997-09-01), None
patent: WO 97/33859 (1997-09-01), None
patent: WO 98/17627 (1998-04-01), None
patent: WO 99/08671 (1999-02-01), None
patent: WO 99/21824 (1999-05-01), None
patent: WO 99/31057 (1999-06-01), None
patent: WO 99/31074 (1999-06-01), None
patent: WO 99/31075 (1999-06-01), None
patent: WO 99/37296 (1999-07-01), None
patent: WO 99/61424 (1999-12-01), None
patent: WO 00/15611 (2000-03-01), None
patent: WO 00/23067 (2000-04-01), None
patent: WO 00/31020 (2000-06-01), None
patent: WO 00/50027 (2000-08-01), None
patent: WO 01/20331 (2001-03-01), None
patent: WO 01/90052 (2001-11-01), None
patent: WO 02/00209 (2002-01-01), None
patent: WO 02/28411 (2002-04-01), None
patent: WO 02/28881 (2002-04-01), None
patent: WO 02/28882 (2002-04-01), None
patent: WO 02/28883 (2002-04-01), None
patent: WO 02/32376 (2002-04-01), None
patent: WO 02/42414 (2002-05-01), None
Adibi, SA, “The Oligopeptide Transporter in Human Intestine: Biology and Function”,Gastroenterology, 1997, vol. 113, pp. 332-340.
Alderman, “A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms”,Int. J. Pharm. Tech.&Prod. Mfr., 1984, vol. 5, No. 3, pp. 1-9.
Bamba et al., “Release Mechanisms in Gelforming Sustained Release Preparations”,Int. J. Pharm., 1979, vol. 2, p. 307.
Bryans et al., “3-substituted GABA Analogs with Central Nervous System Activity: A Review”,Med. Res. Rev., 1999, vol. 19, pp. 149-177.
Coleman et al., “A Practical Guide to Polymer Miscibility”,Polymers, 1990, vol. 31, pp. 1187-1231.
Dieck, ST et al., “The Peptide Transporter PepT2 is Expressed in Rate Brain and Mediates the Accumulation on the Fluorescent Dipeptide Derivative μ-Ala-Lys-Nε-AMCA in Astrocytes”,GLIA, 1999, vol. 25, pp. 10-20.
During et al., “Controlled Release of Dopamine From a Polymeric Brain Implant: In Vivo Characterization”Ann. Neurol., 1989, vol. 25, p. 351.
Fincher, “Particle Size of Drugs and Its Relationship to Absorption and Activity”,J. Pharm. Sci., 1968, vol. 57, pp. 1825-1835.
Gidal et al., “Inter- and Intra-Subject Variability in Gabapentin Absorption and Absolute Bioavailability”,Epilepsy Res., 2000, vol. 40, pp. 123-127.
Gidal et al., “Gabapentin Bioavailability: Effect of Dose and Frequency of Administration in Adult Patients with Epilepsy”,Epilepsy Res., 1998, vol. 31, pp. 91-99.
Goodson, “Dental Applications”,Medical Applications of Controlled Release, 1984, vol. 2, Ch. 6, pp. 115-138.
Hoes, CJT, et al., “The Application of Drug-Polymer Conjugates in Chemotheraphy”,Drug Carrier Systems, 1989, vol. 9, pp. 57-60.
Howard et al., “Intracebral Drug Delivery in Rats With Lesion-Induced Memory Deficits”:,J. Neurosurg., 1989, vol. 71, p. 105.
Jezyk et al., “Transport of Pregabalin in Rat Intestine and Caco-2 Monolayers”,Pharm. Res., 1999, vol. 16, pp. 519-526.
Langer, “New Methods of Drug Delivery”,Science, 1990, vol. 249, pp. 1527-1533.
Langer and Peppas, “Chemical and Physical Structure of Polymers as Carriers of Controlled Release of bioactive Agents: A Review”,JMS-Rev. Macromol. Chem. Phys., 1983, vol. 23, p. 61-126.
Leibach et al., “Peptide Transporters in the Intestine and the Kidney”,Ann. Rev. Nutr., 1996, vol. 16, pp. 99-119.
Leong et al., “Polymeric Controlled Drug Delivery”,Adv. Drug Delivery Rev., 1987, vol. 1, pp. 199-233.
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate”,Science, 1985, vol. 228, p. 190.
Linhardt, R. “Biodegradable Polymers”,Controlled Release of Drugs, 1989, Chp. 2, pp. 53-95.
Lu, “Dimensionless Presentation for Drug Release From a Coated Pure Drug Bead”,Int. J. Pharm., 1994, vol. 112, pp. 117-124.
Magnus, “Nonepileptic Uses of Gabapentin”,Epilepsia, 1999, vol. 40, pp. S66-S72.
Navia and Charurvedi, “Design Principles for Orally Bioavailable Drugs”,Drug Discovery Today, 1996, vol. 1, pp. 179-189.
Radulovic et al., “Disposition of Gabapentin in Mice, Rats, Dogs and Monkeys”,Drug Metab. Dispos., 1995, vol. 23, pp. 441-448.
Remington (editor).Pharmaceutical Sciences, 1970, 14thed. pp. 1626-1628.
Remington (editor),Pharmaceutical Sciences, 1985, 17thed., Ch. 90, pp. 1603-1625.
Seudek et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery”,New England J. of Med., 1989, vol. 321, p. 574.
Sefton, “Implantable Pumps”,CRC Crit. Ref. Biomed. Eng., vol. 14, p. 201.
Tsuji et al., “Carrier-Mediated Intestinal Transport of Drugs”,Pharm. Res., 1996, vol. 13, pp. 963-977.
Verma et al., “Osomotically Controlled Drug Delivery”,Drug Dev. Ind. Pharm., 2000, vol. 26, pp. 695-708.
Wang et al., “Electrophysiological Characteristics of the Proton-Coupled Peptide Transporter PEPT2 Cloned from Rat Brian”,Am. J. Physiol., 1998, vol. 275, pp. C967-C975.
Sugawara Mitsuru et al., “Transport of Valganciclovir, a Ganciclovir Prodrug, via Peptide Transporters PEPT1 and PEPT2”, Journal of Pharmaceutical Sciences, vol. 89, No. 6, Jun. 2000, pp. 781-789, XP001182733.
Praveen V. Balimane et al., “Direct Evidence of Peptide Transporter (Pept1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir”, Biochemical and Biophysical Research Communications, vol. 250, No. 2, Sep. 18, 1998, pp. 246-251, XP000182734.
Hyo-Kyung H
Barrett Ronald W.
Cundy Kenneth C.
Gallop Mark
Scheuerman Randall A.
Zerangue Noa
Aulakh Charanjit S
Buchanan Ingersoll & Rooney P.C.
Xenoport
LandOfFree
Amino acid conjugates providing for sustained systemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino acid conjugates providing for sustained systemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino acid conjugates providing for sustained systemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981659